DK1599469T3 - Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermed - Google Patents
Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermedInfo
- Publication number
- DK1599469T3 DK1599469T3 DK04818324T DK04818324T DK1599469T3 DK 1599469 T3 DK1599469 T3 DK 1599469T3 DK 04818324 T DK04818324 T DK 04818324T DK 04818324 T DK04818324 T DK 04818324T DK 1599469 T3 DK1599469 T3 DK 1599469T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- related disorders
- tetrazole derivatives
- treating metabolism
- metabolism
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51623803P | 2003-10-31 | 2003-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1599469T3 true DK1599469T3 (da) | 2006-10-09 |
Family
ID=34572875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04818324T DK1599469T3 (da) | 2003-10-31 | 2004-10-29 | Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermed |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US8637555B2 (fr) |
| EP (2) | EP1683794A1 (fr) |
| JP (2) | JP4533898B2 (fr) |
| KR (1) | KR100850591B1 (fr) |
| CN (1) | CN1867562B (fr) |
| AR (1) | AR046611A1 (fr) |
| AT (1) | ATE328880T1 (fr) |
| AU (1) | AU2004287861B2 (fr) |
| BR (1) | BRPI0415631A (fr) |
| CA (1) | CA2539985C (fr) |
| CO (1) | CO5690551A2 (fr) |
| CR (1) | CR8270A (fr) |
| CY (1) | CY1105479T1 (fr) |
| DE (1) | DE602004001134T2 (fr) |
| DK (1) | DK1599469T3 (fr) |
| EA (1) | EA011484B1 (fr) |
| EC (1) | ECSP066529A (fr) |
| ES (1) | ES2267077T3 (fr) |
| GE (1) | GEP20094801B (fr) |
| HK (1) | HK1076468A1 (fr) |
| HR (1) | HRP20060286T3 (fr) |
| IL (1) | IL174042A0 (fr) |
| IS (1) | IS2372B (fr) |
| MA (1) | MA28171A1 (fr) |
| MX (1) | MXPA06004556A (fr) |
| MY (1) | MY140410A (fr) |
| NO (1) | NO20062509L (fr) |
| NZ (1) | NZ546285A (fr) |
| PE (1) | PE20050483A1 (fr) |
| PL (1) | PL1599469T3 (fr) |
| PT (1) | PT1599469E (fr) |
| RS (1) | RS20060290A (fr) |
| SI (1) | SI1599469T1 (fr) |
| TN (1) | TNSN06150A1 (fr) |
| TW (1) | TWI258478B (fr) |
| UA (1) | UA86783C2 (fr) |
| WO (1) | WO2005044816A1 (fr) |
| ZA (2) | ZA200603419B (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20050483A1 (es) | 2003-10-31 | 2005-08-25 | Arena Pharm Inc | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas |
| DE602004022864D1 (de) | 2003-11-21 | 2009-10-08 | Arena Pharm Inc | 4-oxo-4,5-dihydro-furan-2-carbonsäure und derivate und verfahren zur behandlung von stoffwechselerkrankungen mit diesen verbindungen |
| WO2006026273A2 (fr) * | 2004-08-25 | 2006-03-09 | Merck & Co., Inc. | Procede pour traiter l'atherosclerose, la dyslipidemie et les etats pathologiques associes |
| JP2008519080A (ja) * | 2004-11-05 | 2008-06-05 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ナイアシン受容体部分的アゴニストを含む、潮紅および脂質関連障害を処置するための組成物 |
| PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| US8168799B2 (en) | 2005-04-28 | 2012-05-01 | Merck Sharpe & Dohme Ltd. | Process for the preparation of tetrazolytetrahydrocyclopentapyrazoles |
| US8168649B2 (en) | 2005-06-28 | 2012-05-01 | Merk Sharp & Dohme Corp. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| DE102006021733A1 (de) * | 2006-05-09 | 2007-11-22 | Bayer Healthcare Ag | 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung |
| DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
| DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| JP2015522080A (ja) | 2012-07-11 | 2015-08-03 | エルセリクス セラピューティクス インコーポレイテッド | スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物 |
| EP3760629A1 (fr) | 2013-02-21 | 2021-01-06 | Adverio Pharma GmbH | Formes du {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}méthylcarbamate de méthyle |
| WO2015012210A1 (fr) * | 2013-07-23 | 2015-01-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Composé cyclique hétérocondensé |
| CN103755637A (zh) * | 2013-12-26 | 2014-04-30 | 平湖优康药物研发有限公司 | 一种医药中间体1,4,5,6-四氢-3-环戊并吡唑甲腈的合成工艺 |
| CA3096145A1 (fr) * | 2019-10-11 | 2021-04-11 | Royal Bank Of Canada | Systeme et methode d`apprentissage automatique utilisant des reseaux de plongements |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02178263A (ja) * | 1988-12-27 | 1990-07-11 | Kaken Pharmaceut Co Ltd | アザアズレン誘導体、その製造法およびそれを有効成分とする抗アレルギー剤および抗炎症剤 |
| US5134155A (en) | 1991-08-08 | 1992-07-28 | Ortho Pharmaceutical Corporation | Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors |
| US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
| PL334250A1 (en) | 1996-12-23 | 2000-02-14 | Du Pont Pharm Co | Nitrogen containing hetero-aromatic compounds and inhibitors of xa factor |
| AU3275999A (en) | 1998-03-10 | 1999-09-27 | Ono Pharmaceutical Co. Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
| US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| JP4292742B2 (ja) | 2000-03-09 | 2009-07-08 | 小野薬品工業株式会社 | インドール誘導体、その製造方法および用途 |
| WO2003022814A1 (fr) | 2001-09-07 | 2003-03-20 | Ono Pharmaceutical Co., Ltd. | Derives d'indole |
| US20010047027A1 (en) | 2000-04-12 | 2001-11-29 | Marc Labelle | Prostaglandin D2 receptor antagonists |
| US6699997B2 (en) | 2000-06-28 | 2004-03-02 | Teva Pharmaceutical Industries Ltd. | Carvedilol |
| US7157466B2 (en) | 2000-06-30 | 2007-01-02 | Smithkline Beecham (Cork) Limited | Quinazoline ditosylate salt compounds |
| US6410583B1 (en) | 2000-07-25 | 2002-06-25 | Merck Frosst Canada & Co. | Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
| DE10057751A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Carbamat-substituierte Pyrazolopyridinderivate |
| JP4279561B2 (ja) | 2001-05-23 | 2009-06-17 | メルク フロスト カナダ リミテツド | プロスタグランジンＤ２受容体拮抗薬としてのジヒドロピロロ［１，２−ａ］インドールおよびテトラヒドロピリド［１，２−ａ］−インドール誘導体 |
| ES2332505T3 (es) | 2001-06-01 | 2010-02-08 | F. Hoffmann-La Roche Ag | Derivados de pirimidina, triazina y pirazina como receptores de glutamato. |
| CA2451128A1 (fr) | 2001-06-26 | 2003-01-09 | Bristol-Myers Squibb Company | Inhibiteurs n-heterocycliques d'expression tnf-alpha |
| US6884750B2 (en) | 2001-06-27 | 2005-04-26 | Rs Tech Corp. | Chiral salen catalyst and methods for the preparation of chiral compounds from racemic epoxides by using new catalyst |
| DE10148617A1 (de) | 2001-09-25 | 2003-04-24 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
| AR038136A1 (es) | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
| CN100378083C (zh) | 2002-03-19 | 2008-04-02 | 小野药品工业株式会社 | 羧酸化合物和含有所述化合物作为活性成分的药物制剂 |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| AU2003282679A1 (en) | 2002-10-04 | 2004-05-04 | Arena Pharmaceuticals, Inc. | Hydroxypyrazoles for use against metabolic-related disorders |
| AU2003300014A1 (en) * | 2002-10-10 | 2004-05-04 | Arena Pharmaceuticals, Inc. | 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia |
| DE10261131A1 (de) | 2002-12-20 | 2004-07-01 | Grünenthal GmbH | Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| AR041089A1 (es) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| WO2005011677A1 (fr) | 2003-06-13 | 2005-02-10 | Arena Pharmaceuticals, Inc. | Derives d'acide 2h-pyrazol-3- carboxylique substitues en 5 utilises comme agonistes du recepteur de l'acide nicotinique rup25 pour le traitement des dyslipidemies et des pathologies apparentees |
| GB0319126D0 (en) | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
| GB0319124D0 (en) | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
| PE20050483A1 (es) | 2003-10-31 | 2005-08-25 | Arena Pharm Inc | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas |
| CA2556073C (fr) | 2004-02-14 | 2012-01-10 | Smithkline Beecham Corporation | Composes |
| WO2006026273A2 (fr) | 2004-08-25 | 2006-03-09 | Merck & Co., Inc. | Procede pour traiter l'atherosclerose, la dyslipidemie et les etats pathologiques associes |
| JP2008519080A (ja) | 2004-11-05 | 2008-06-05 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ナイアシン受容体部分的アゴニストを含む、潮紅および脂質関連障害を処置するための組成物 |
| PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| US8168799B2 (en) | 2005-04-28 | 2012-05-01 | Merck Sharpe & Dohme Ltd. | Process for the preparation of tetrazolytetrahydrocyclopentapyrazoles |
-
2004
- 2004-10-27 PE PE2004001031A patent/PE20050483A1/es not_active Application Discontinuation
- 2004-10-27 TW TW093132486A patent/TWI258478B/zh not_active IP Right Cessation
- 2004-10-28 MY MYPI20044462A patent/MY140410A/en unknown
- 2004-10-29 DE DE602004001134T patent/DE602004001134T2/de not_active Expired - Lifetime
- 2004-10-29 EP EP06005248A patent/EP1683794A1/fr not_active Withdrawn
- 2004-10-29 ES ES04818324T patent/ES2267077T3/es not_active Expired - Lifetime
- 2004-10-29 WO PCT/US2004/035927 patent/WO2005044816A1/fr active IP Right Grant
- 2004-10-29 RS YUP-2006/0290A patent/RS20060290A/sr unknown
- 2004-10-29 CA CA2539985A patent/CA2539985C/fr not_active Expired - Fee Related
- 2004-10-29 DK DK04818324T patent/DK1599469T3/da active
- 2004-10-29 CN CN2004800299376A patent/CN1867562B/zh not_active Expired - Fee Related
- 2004-10-29 GE GEAP20049421A patent/GEP20094801B/en unknown
- 2004-10-29 MX MXPA06004556A patent/MXPA06004556A/es active IP Right Grant
- 2004-10-29 BR BRPI0415631-5A patent/BRPI0415631A/pt not_active IP Right Cessation
- 2004-10-29 AU AU2004287861A patent/AU2004287861B2/en not_active Ceased
- 2004-10-29 JP JP2006536942A patent/JP4533898B2/ja not_active Expired - Fee Related
- 2004-10-29 AR ARP040103978A patent/AR046611A1/es unknown
- 2004-10-29 EA EA200600879A patent/EA011484B1/ru not_active IP Right Cessation
- 2004-10-29 PT PT04818324T patent/PT1599469E/pt unknown
- 2004-10-29 US US10/535,345 patent/US8637555B2/en not_active Expired - Fee Related
- 2004-10-29 KR KR1020067008311A patent/KR100850591B1/ko not_active IP Right Cessation
- 2004-10-29 NZ NZ546285A patent/NZ546285A/en not_active IP Right Cessation
- 2004-10-29 AT AT04818324T patent/ATE328880T1/de active
- 2004-10-29 EP EP04818324A patent/EP1599469B1/fr not_active Expired - Lifetime
- 2004-10-29 SI SI200430058T patent/SI1599469T1/sl unknown
- 2004-10-29 PL PL04818324T patent/PL1599469T3/pl unknown
- 2004-10-29 UA UAA200605989A patent/UA86783C2/ru unknown
-
2005
- 2005-12-06 HK HK05111162A patent/HK1076468A1/xx not_active IP Right Cessation
-
2006
- 2006-03-01 IL IL174042A patent/IL174042A0/en unknown
- 2006-03-03 CR CR8270A patent/CR8270A/es not_active Application Discontinuation
- 2006-03-30 CO CO06031620A patent/CO5690551A2/es not_active Application Discontinuation
- 2006-04-28 EC EC2006006529A patent/ECSP066529A/es unknown
- 2006-04-28 ZA ZA200603419A patent/ZA200603419B/en unknown
- 2006-05-22 TN TNP2006000150A patent/TNSN06150A1/en unknown
- 2006-05-23 MA MA29049A patent/MA28171A1/fr unknown
- 2006-05-24 IS IS8481A patent/IS2372B/is unknown
- 2006-05-31 NO NO20062509A patent/NO20062509L/no not_active Application Discontinuation
- 2006-07-26 ZA ZA200606203A patent/ZA200606203B/xx unknown
- 2006-08-24 HR HR20060286T patent/HRP20060286T3/xx unknown
- 2006-09-05 CY CY20061101259T patent/CY1105479T1/el unknown
- 2006-11-17 US US11/601,252 patent/US20070072924A1/en not_active Abandoned
-
2010
- 2010-03-10 JP JP2010053852A patent/JP2010163448A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1644021T3 (da) | Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme | |
| NO20055211D0 (no) | Anti-fungale forbindelser og fremgangsmater for anvendelse | |
| DK1667986T3 (da) | Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf | |
| DK1824475T3 (da) | Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol | |
| DK1606283T3 (da) | P38-inhibitorer og fremgangsmåder til anvendelse deraf | |
| IS2675B (is) | P38-hindrar og aðferðir til notkunar þeirra | |
| DK1805312T3 (da) | Fremgangsmåder og midler til fremstilling af hyaluronan | |
| DK1663978T3 (da) | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser | |
| DK1628530T3 (da) | Fremgangsmåder og sammensætninger til forebyggelse og behandling af sepsis | |
| DK1673104T4 (da) | Fremføring af terapeutiske forbindelser til hjernen og andre væv | |
| DK1583542T3 (da) | Sammensætninger og fremgangsmåder til antiviral kombinationsterapi | |
| DK1891571T3 (da) | Hæmning af spredning af uønskede koder og data | |
| DK1803718T3 (da) | 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter | |
| DK1830838T3 (da) | Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme | |
| DK1706112T3 (da) | Fremgangsmåder til at behandle en inflammatorisk-beslægtet sygdom | |
| DK1997512T3 (da) | Fremgangsmåder til behandling af TWEAK-relaterede tilstande | |
| DK1599469T3 (da) | Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermed | |
| IS8497A (is) | Aðferðir og hvarfefni til að meðhöndla bólgusjúkdóma | |
| DK1701944T3 (da) | 2-(amino-substituerede)-4-aryl-pyramidiner og relaterede forbindelser til behandling af inflammationssygdomme | |
| DK1596868T3 (da) | Fremgangsmåde til behandling af hjertesvigt og medikament dertil | |
| DE602005001520D1 (de) | Zeiteinstellungssystem und Zeiteinstellungsverfahren | |
| DK1478438T3 (da) | Fremgangsmåder og sammensætninger til behandling af astma | |
| DK1589973T4 (da) | Formulering og fremgangsmåder til behandling af thrombocytæmi | |
| DK1750713T3 (da) | Anvendelse af imatinib til behandling af leversygdomme og vi-rusinfektioner | |
| DK1611890T3 (da) | Fremgangsmåde til evaluering og behandling af cancer |